Spotlight on pioglitazone in type 2 diabetes mellitus.

Abstract

Pioglitazone (Actos(trade mark)) is an antihyperglycemic agent that, in the presence of insulin resistance, increases hepatic and peripheral insulin sensitivity, thereby inhibiting hepatic gluconeogenesis and increasing peripheral and splanchnic glucose uptake. Pioglitazone is generally well tolerated, weight gain and edema are the most common emergent adverse events, and there are no known drug interactions between pioglitazone and other drugs. In clinical trials in patients with type 2 diabetes mellitus, pioglitazone as monotherapy, or in combination with metformin, repaglinide, insulin, or a sulfonylurea, induced both long- and short-term improvements in glycemic control and serum lipid profiles. Pioglitazone was also effective in reducing some measures of cardiovascular risk and arteriosclerosis. Pioglitazone thus offers an effective treatment option for the management of patients with type 2 diabetes.

• Authors: John Waugh, Gillian M Keating, Greg L Plosker, Stephanie Easthope, Dean M Robinson
• Journal: Treatments in endocrinology (Treat Endocrinol) Vol. 5 Issue 3 Pg. 189-91 ( 2006) ISSN: 1175-6349 [Print] New Zealand
• PMID: 16677060 (Publication Type: Journal Article)

Chemical References

• Blood Glucose
• Hypoglycemic Agents
• Metformin

Topics

• Blood Glucose
• Cardiovascular Diseases (chemically induced)
• Diabetes Mellitus, Type 2 (blood)
• Humans
• Hypoglycemic Agents (administration & dosage)
• Metformin (administration & dosage)
• Risk Factors